Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | LAP3 | P28838 | 4/20 | 0.41 |
| ▸ | ANPEP | P15144 | 5/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.37 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.37 |
| ▸ | CTRB1 | P17538 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alafosfalin SCHEMBL1582303 | 1.00 | DPP4 (0.48) | DPP4LAP3ANPEPCA12CA1 | |
| Alafosfalin SCHEMBL456724 | 1.00 | DPP4 (0.48) | DPP4LAP3ANPEPCA12CA1 | |
| Alafosfalin SCHEMBL11032329 | 1.00 | DPP4 (0.48) | DPP4LAP3ANPEPCA12CA1 | |
| Alafosfalin SCHEMBL9619892 | 0.98 | DPP4 (0.47) | DPP4LAP3ANPEPCA12CA1 | |
| Alafosfalin SCHEMBL11297483 | 0.98 | DPP4 (0.47) | DPP4LAP3ANPEPCA12CA1 | |
| SCHEMBL11299128 | 0.92 | DPP4 (0.42) | DPP4LAP3ANPEPCA12CA1 | |
| SCHEMBL18919534 | 0.92 | DPP4 (0.42) | DPP4LAP3ANPEPCA12CA1 | |
| SCHEMBL1582769 | 0.92 | DPP4 (0.42) | DPP4LAP3ANPEPCA12CA1 | |
| SCHEMBL1582242 | 0.92 | DPP4 (0.42) | DPP4LAP3ANPEPCA12CA1 | |
| SCHEMBL11296889 | 0.86 | PAX8 (0.40) | DPP4LAP3ANPEPDPP8DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 309 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210163959-A1 | EXPRESSION OF PROTEINS IN GRAM-NEGATIVE BACTERIA WHEREIN THE RATIO OF PERIPLASMIC VOLUME TO CYTOPLASMIC VOLUME IS BETWEEN 0.5:1 AND 10:1 | GELTOR, INC. | 2021-06-03 | — | — | US | claimed |
| US-10941406-B2 | Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1 | GELTOR, INC. (US) | 2021-03-09 | — | — | US | claimed |
| CN-110522914-A | The treatment of pharmaceutical composition and mazoitis | BAYER ANIMAL HEALTH GMBH | 2019-12-03 | — | — | CN | claimed |
| US-10265330-B2 | Pharmaceutical compositions and treatment of mastitis | BAYER ANIMAL HEALTH GMBH (DE) | 2019-04-23 | — | — | US | claimed |
| US-20190106702-A1 | EXPRESSION OF PROTEINS IN GRAM-NEGATIVE BACTERIA WHEREIN THE RATIO OF PERlPLASMIC VOLUME TO CYTOPLASMIC VOLUME IS BETWEEN 0.5:1 AND 10:1 | GELTOR, INC. | 2019-04-11 | — | — | US | claimed |
| EP-3436610-A1 | EXPRESSION OF PROTEINS IN GRAM-NEGATIVE BACTERIA WHEREIN THE RATIO OF PERIPLASMIC VOLUME TO CYTOPLASMIC VOLUME IS BETWEEN 0.5:1 AND 10:1 | Geltor, Inc. (US) | 2019-02-06 | — | — | EP | claimed |
| CN-109312299-A | Expression of the protein in the Gram-negative bacteria of pericentral siphon volume and plasma volume ratio with 0.5:1 to 10:1 | 格尔托公司 | 2019-02-05 | — | — | CN | claimed |
| WO-2017172994-A1 | EXPRESSION OF PROTEINS IN GRAM-NEGATIVE BACTERIA WHEREIN THE RATIO OF PERIPLASMIC VOLUME TO CYTOPLASMIC VOLUME IS BETWEEN 0.5:1 AND 10:1 | GELTOR, INC. (US) | 2017-10-05 | — | — | WO | claimed |
| US-20150164926-A1 | PHARMACEUTICAL COMPOSITIONS AND TREATMENT OF MASTITIS | ELANCO ANIMAL HEALTH GMBH (DE) | 2015-06-18 | — | — | US | claimed |
| EP-2866812-A1 | PHARMACEUTICAL COMPOSITIONS AND TREATMENT OF MASTITIS | Bayer Animal Health GmbH (DE) | 2015-05-06 | — | — | EP | claimed |
| EP-1497272-A4 | METHOD OF PREPARING AMINE STEREOISOMERS | APSINTERM LLC (US) | 2007-02-07 | — | — | EP | claimed |
| US-7129378-B2 | Method of preparing amine stereoisomers | APSINTERM, LLC (US) | 2006-10-31 | — | — | US | claimed |
| CN-1659154-A | Process for the preparation of amine stereoisomers | APSINTERM LLC (US) | 2005-08-24 | — | — | CN | claimed |
| US-20050165240-A1 | Method of preparing amine stereoisomers | APSINTERM, LLC | 2005-07-28 | — | — | US | claimed |
| EP-1497272-A2 | METHOD OF PREPARING AMINE STEREOISOMERS | Apsinterm, LLC. (US) | 2005-01-19 | — | — | EP | claimed |
| WO-2003091207-A2 | METHOD OF PREPARING AMINE STEREOISOMERS | APSINTERM, LLC. (US) | 2003-11-06 | — | — | WO | claimed |
| EP-1325024-A1 | SELECTIVE GROWTH MEDIA | The Newcastle upon Tyne Hospitals National Health Service Trust (GB) | 2003-07-09 | — | — | EP | claimed |
| WO-2002024725-A1 | SELECTIVE GROWTH MEDIA | NEWCASTLE UPON TYNE HOSPITALS NHS TRUST (GB) | 2002-03-28 | — | — | WO | claimed |
| US-4127649-A | PEPTIDES | HOFFMANN-LA ROCHE INC. (US) | 1978-11-28 | — | — | US | claimed |
| US-4100275-A | PEPTIDES | HOFFMANN-LA ROCHE INC. (US) | 1978-07-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165240-A1 | Method of preparing amine stereoisomers | SRM, TST, SMOX | DPP4 4826/4885LAP3 2874/4885ANPEP 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.